Baudax Bio(NASDAQ) BXRX

Market CapN/A

Since IPO (2019)-100%

5 Year-100%

1 Year+0%

1 Month+0%

N/A

Baudax Bio last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-10-13

Baudax Bio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-10-06
1 month	+0%	USD 0.00	2026-09-10
3 month	+0%	USD 0.00	2026-07-13
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-10-13
3 year	-100%	USD 0.26	2023-10-13
5 year	-100%	USD 797.20	2021-10-14
Since inception	-100%	USD 8,470.01	2019-11-18

Baudax Bio Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$326.00K

Net Income (TTM)

-$7.15M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 18, 2024

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 18, 2024

BXRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Baudax Bio

Baudax Bio, Inc. is a pharmaceutical company focused on developing and marketing therapeutic solutions for inpatient and urgent care settings. The company’s flagship product, ANJESO, is an injectable meloxicam formulation aimed at managing moderate to severe pain.

Products and Services

ANJESO: Injectable meloxicam for pain management
BX1000: Intermediate-acting neuromuscular blocker in Phase II trials
BX2000: Ultra-short-acting neuromuscular blocker in Phase I trials

Growth Outlook

Continued development of innovative pain management solutions
Expansion of clinical trials for neuromuscular blockers
Potential market growth in the urgent care sector

Financial Highlights

Q3 2023 revenue of $0, reflecting ongoing investment in R&D
Net income for Q3 2023 was -$1.93 million, indicating operational challenges
Cash and cash equivalents decreased to $363,000 by Q3 2023

Baudax Bio, Inc. operates in the biotechnology sector, with a focus on addressing unmet medical needs in pain management. The company’s flagship product, ANJESO, is designed to provide effective pain relief, which is critical in both inpatient and urgent care environments. The ongoing development of additional neuromuscular blockers and innovative delivery systems positions Baudax Bio for potential growth in a competitive market. Despite facing financial challenges, including a net income loss in recent quarters, the company continues to invest in research and development. This commitment to innovation may lead to future product offerings that could enhance revenue streams. The current cash position indicates a need for careful financial management as the company navigates its growth trajectory. Overall, Baudax Bio presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in pain management solutions.

AI Generated • Sep 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Gerri Henwood

Website

www.baudaxbio.com

Headquarters

Malvern, PA 19355, US

BXRX Financials

Key Financial Metrics (TTM)

Gross Margin

-452.32%

Operating Margin

-4476.99%

Net Income Margin

-4633.18%

Return on Equity

1067.45%

Return on Capital

N/A

Return on Assets

-586.07%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$5.02M

Operating Income

-$22.11M

EBITDA

-$32.02M

Operating Cash Flow

-$14.31M

Capital Expenditure

$40.00K

Free Cash Flow

-$14.27M

Cash & ST Invst.

$363.00K

Total Debt

$8.10M

Baudax Bio Performance Analysis

Baudax Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 1,080,000	N/A
2022	2022-12-31	USD 1,269,000	17.5%

Baudax Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	30.3%
Q1	2023-03-31	-104.5%
Q2	2023-06-30	314.3%
Q3	2023-09-30	-100.0%

Baudax Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -405.40	N/A
2022	2022-12-31	USD -177.30	-56.3%

Baudax Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	94.2%
Q1	2023-03-31	186.1%
Q2	2023-06-30	-130.8%
Q3	2023-09-30	84.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2023YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$43.00K

+95.6%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$1.93M

+93.4%

EBITDA

-$43.00K

+99.3%

Quarterly Fundamentals

Name

Q3 2023YOY CHG

Total Cash

$363.00K

-93.6%

Total Debt

$8.10M

+0.1%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$2.53M

+16.2%

Short Term Debt

$5.57M

-5.8%

Return on Assets

-5.86%

N/A

Return on Invested Capital

4.97%

N/A

Free Cash Flow

-$2.41M

+38.3%

Operating Cash Flow

-$2.41M

+37.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NVIVInVivo Therapeutics Holdings Corporation

NVIVInVivo Therapeutics Holdings Corporation$0.32-34.28%

NMTRQ9 Meters Biopharma, Inc.

NMTRQ9 Meters Biopharma, Inc.$0.00+0.00%

INFIQInfinity Pharmaceuticals, Inc.

INFIQInfinity Pharmaceuticals, Inc.$0.00+0.00%

CWBRCohBar, Inc.

CWBRCohBar, Inc.$0.41+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

BACBank of America

BACBank of America$49.81-7.69%

CRWVCoreWeave

CRWVCoreWeave$67.37-13.42%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$40.21+7.46%

SOFISoFi Technologies

SOFISoFi Technologies$14.35-5.87%

CIFRCipher Digital

CIFRCipher Digital$10.63-6.27%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$118.09-7.43%

IRENIren

IRENIren$32.02-7.99%

Questions About BXRX

What is the current price of Baudax Bio?

Baudax Bio is trading at N/A per share.

What is the 52-week range for Baudax Bio?

Over the past 52 weeks, Baudax Bio has traded between N/A and N/A.

How much debt does Baudax Bio have?

As of the most recent reporting period, Baudax Bio reported total debt of $7.12M.

How much cash does Baudax Bio have on hand?

Baudax Bio reported $5.26M in cash and cash equivalents in its most recent financial results.

What is Baudax Bio’s dividend yield?

Baudax Bio does not currently have a dividend yield.

Baudax Bio(NASDAQ) BXRX

Baudax Bio Financials at a Glance

BXRX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Baudax Bio

BXRX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Baudax Bio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BXRX

What is the current price of Baudax Bio?

What is the 52-week range for Baudax Bio?

How much debt does Baudax Bio have?

How much cash does Baudax Bio have on hand?

What is Baudax Bio’s dividend yield?

Premium Investing Services